Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors
Active, not recruiting · NCT03875287 · Registry updated 2026-09-08Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Dose-Escalation Study of E7727, an Oral Cytidine Deaminase Inhibitor With Oral Decitabine in Subjects With Solid Tumors | Solid Tumor | Active, not recruiting | Phase 1 | 2026-09-08 | NCT03875287 |
3 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Astex Pharmaceuticals, Inc. | 12 |
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 117 |
| Stand Up To Cancer | 20 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Baltimore | United States | 8 |
| Usc Norris Comprehensive Cancer Center | Los Angeles | United States | 11 |